Please use this identifier to cite or link to this item:
Title: Use of surodex in phacotrabeculectomy surgery
Authors: Seah, S.K.L.
Husain, R.
Lim, M.C.C.
Hoh, S.-T.
Oen, F.T.S.
Aung, T. 
Gazzard, G.
Issue Date: 2005
Citation: Seah, S.K.L., Husain, R., Lim, M.C.C., Hoh, S.-T., Oen, F.T.S., Aung, T., Gazzard, G. (2005). Use of surodex in phacotrabeculectomy surgery. American Journal of Ophthalmology 139 (5) : 927-928. ScholarBank@NUS Repository.
Abstract: PURPOSE: To evaluate the use of Surodex (Oculex Pharmaceuticals, Sunnyvale, California) a drug delivery system incorporating 60 micrograms of dexamethasone in a pellet, in phacotrabeculectomy surgery. DESIGN: Nonrandomized, prospective, interventional case series. METHODS: Phacotrabeculectomy was performed on 37 Asian subjects with primary open-angle glaucoma (POAG) using a standardized technique. All subjects received a Surodex pellet underneath the scleral flap. Results were compared with those of 31 POAG subjects who had undergone phacotrabeculectomy augmented with 50 mg/ml of intraoperative 5-fluorouracil (5-FU) during the same period. RESULTS: Mean follow-up in months was 19.7 ± 7.9 and 22.1 ± 6.2 for the Surodex and 5-FU groups, respectively (P = .29). There was a 20.1% decrease in intraocular pressure in the Surodex group compared with 28.5% decrease in the 5-FU group (P = .6). Postoperative complications occurred in three cases (8.1%) and six cases (19.3%), respectively (P = .04). CONCLUSIONS: Combined phacotrabeculectomy surgery augmented by intra-scleral placement of Surodex results in good control of IOP and a low incidence of complications. © 2005 by Elsevier Inc. All rights reserved.
Source Title: American Journal of Ophthalmology
ISSN: 00029394
DOI: 10.1016/j.ajo.2004.10.052
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on May 30, 2023


checked on May 30, 2023

Page view(s)

checked on May 25, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.